Pituitary, Gonad, Adrenal and Neuroendocrine

2022 Consensus Statement on Immune Checkpoint Inhibitor-Mediated Endocrinopathies

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews the clinical presentation of ICI-related endocrinopathies; and discusses the diagnosis and management approaches to endocrinopathies related to ICI therapy.

2020 Position Statement on Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem

Pituitary, Gonad, Adrenal and Neuroendocrine
Position Statements
This position statement raises awareness about the risks of off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. This statement distinguishes off-label hormone use from legitimate use for diagnoses such as male hypogonadism, growth hormone deficiency, hypothyroidism, and adrenal insufficiency.

2020 Consensus Statement on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This consensus statement provides a practical approach to management of patients with newly diagnosed adrenocortical carcinoma, as well as follow-up and management of patients with persistent or recurrent disease, including the management of an adrenal mass, presurgical evaluation, surgical approach, pathologic assessment, and other therapeutic modalities, based on individual patient presentation.

2019 Clinical Practice Guideline for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care

Pituitary, Gonad, Adrenal and Neuroendocrine
Clinical Practice Guidelines
Podcasts
This guideline provides recommendations on identification, screening, assessment, diagnosis, and treatment of a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care. The guideline summarizes current knowledge about the accuracy of available GH–stimulation tests, safety of recombinant human GH (rhGH) replacement, unapproved uses of rhGH related to sports and aging, and new developments such as long-acting GH preparations that use a variety of technologies to prolong GH action.

2019 Consensus Statement on the Evaluation of Incidentally Discovered Adrenal Masses

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This consensus statement provides a practical approach to the evaluation of incidentally discovered adrenal masses, presenting five patient case scenarios selected to highlight a unique and relatively characteristic presentation that clinicians may encounter and answering key questions to help guide evaluation, diagnosis, management, and treatment.

2017 Endocrine Society Clinical Practice Guideline on Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons

Pituitary, Gonad, Adrenal and Neuroendocrine
Clinical Practice Guidelines
Co-sponsored Clinical Guidance
This 2017 guideline‒led by the Endocrine Society and co-sponsored with AACE, American Society of Andrology, European Society for Pediatric Endocrinology, European Society of Endocrinology, Pediatric Endocrine Society, and World Professional Association for Transgender Health‒is an update of the 2009 Endocrine Society guideline on endocrine treatment of transsexual persons. An update of this guideline is in development.

2017 Consensus Statement on Transgender Medicine

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
These six case discussions present clinical vignettes to illustrate some of the key recommendations for diagnosis, treatment, and long-term management of transgender children and adults in the Endocrine Society's 2017 guideline, co-sponsored by AACE, on endocrine treatment of persons with gender dysphoria/gender incongruence.

2015 Consensus Statement for Pre-Operative Therapy in Management of Patients with Acromegaly

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This statement addresses the use of somatostatin-receptor ligands (SRLs) as preoperative therapy for individuals with acromegaly to improve outcomes.

2015 Consensus Statement on Macroprolactin

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This statement addresses the prevalence of macroprolactin in patients with hyperprolactinemia and macroprolactin’s relevance regarding clinical decision-making about laboratory testing, imaging, and pharmacologic or surgical treatment.

2015 Consensus Statement on Traumatic Brain Injury

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This statement addresses neuroendocrine evaluation, testing, and management of patients with traumatic brain injury‒induced hypopituitarism or those at risk for hypopituitarism.

2015 Consensus Statement on MEN Thyroidectomy

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This statement employs case studies to discuss evaluation, early diagnosis, surgical treatment, and ongoing management of endocrinopathies in patients with multiple endocrine neoplasia, type 2.

2015 Consensus Statement on Midgut Carcinoids

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
Carcinoid tumors, which most commonly originate from the small intestine, are either referred to as small intestinal neuroendocrine tumors or midgut carcinoids. This statement addresses diagnostics and therapeutics for patients with midgut carcinoids and provides an overview of multidisciplinary care to improve quality of life, treatment outcomes, and survival.

2015 Consensus Statement on Pancreatic Incidentalomas

Pituitary, Gonad, Adrenal and Neuroendocrine
Consensus Statements
This statement addresses incidental detection of pancreatic neuroendocrine tumors, imaging-based characterization for differential diagnoses, prognosis, and appropriate management.

Endorsed Clinical Guidance

Bone and Parathyroid
Cardiometabolic and Lipids
Diabetes
Nutrition and Obesity
Pituitary, Gonad, Adrenal and Neuroendocrine
Thyroid
Co-sponsored Clinical Guidance
Endorsed Clinical Guidance
After careful review, AACE may endorse clinical guidance documents developed by external organizations to provide up-to-date recommendations for practice or valuable ancillary knowledge for AACE members and their teams to improve care of patients. Endorsements are reviewed and approved by AACE leadership.